雲嘉南地區沿海地帶的膀胱癌病例是台灣之冠。目前表淺非肌肉侵犯型膀胱癌術後膀胱內化學藥物灌注的常用藥劑是Mitomycin-C、Doxorubicin 及Cisplatin，但是這些化學藥物會引起頻尿、尿急、血尿等副作用，因此想要尋求傳統中藥中能替代化學治療的藥物，使膀胱癌患者能在更少的副作用下得到更好的療效。我們選擇桂枝茯苓丸來與Mitomycin-C、Doxorubicin 及Cisplatin 作比較。在人類膀胱癌細胞株及正常人類泌尿道上皮細胞株的生長抑制實驗裡，我們利用CCK-8 法來觀察各組細胞存活率，並計算出SI 值來判斷不同藥物的選擇性抗癌活性。結果顯示桂枝茯苓丸不但與這些膀胱灌注化療藥物一樣有抑制人類膀胱癌細胞株生長的效果，而且有更高的選擇性來抑制人類膀胱癌細胞株的生長。

Bladder cancer is the second most common malignancy of the genitourinary tract in Taiwan. Treatment for superficial non-invasive bladder carcinoma is currently using intravesical instillations of Mitomycin-C、Doxorubicin or Cisplatin after transurethral resection of bladder tumor. However, these therapy drugs usually cause major side effects including urinary frequency, urinary urgency, cystitis and hematuria. Therefore, we intend to identify a traditional Chinese medicine which would also inhibit tumour cell proliferation but have less cytotoxic effects than cancer chemotherapy drugs. Guizhi Fuling Wan (GFW), which is a well-known traditional Chinese medicine, has been shown to inhibit the growth of hepatocellular carcinoma and cervical cancer, but lack of knowledge about its effect on bladder carcinoma. The cell viability was analyzed with CCK-8 assay. Our data suggested that GFW is an effective agent to inhibit the proliferation of bladder cancer cells. In addition, its relatively high selectivity to cancer cells and minimal toxicity to normal urothelial cells suggests that GFW may be a good candidate agent for intravesicle chemotherapy in bladder cancer.